Background: The aim of this study was to explore the association between single nucleotide polymorphisms (SNPs) in the rs120963, rs152451, rs249935, rs447529, rs8053188, and rs16940342 loci in the PALB2 gene and breast cancer risk. Methods: Studies investigating the association between SNPs in the PALB2 gene and breast cancer susceptibility were retrieved from the PubMed, Embase, Web of Science, CNKI (Chinese National Knowledge Infrastructure), WanFang, and CBM (China Biology Medicine) databases. Eligible studies were screened according to inclusion/exclusion criteria and principles of quality evaluation. Meta-analysis was performed using Stata 14.0 software. Odds ratios with their corresponding 95% confidence intervals were pooled to assess the association between SNPs in the PALB2 gene loci rs249935, rs447529, rs8053188, rs16940342, rs152451, and rs120963 and breast cancer susceptibility. Results: A total of 9 case-control studies were eligible for this meta-analysis. SNPs in the PALB2 gene loci rs120963, rs249935, and rs447529 were significantly associated with an increased or decreased risk of breast cancer. No significant association was detected for rs152451, rs8053188, and rs16940342 under 4 genetic models. Conclusion: The results of this study suggest that SNPs in the PALB2 loci rs120963/rs249935/rs447529, but not in the other 3 loci (rs152451/rs8053188/rs16940342), may contribute to breast cancer susceptibility.

Journal Section:
Research Article
Keywords:
Breast cancer, PALB2, Polymorphism, Meta-analysis
1.
Torre L A, Bray F, Siegel RL, et al.: Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
[PubMed]
https://doi.org/10.3322/caac.21262
2.
Lee J, Li N, Rowley SM, et al.: Molecular analysis of PALB2-associated breast cancers. J Pathol 2018;245:53-60.
[PubMed]
https://doi.org/10.1002/path.5055
3.
Leyton Y, Gonzalez-Hormazabal P, Blanco R, et al.: Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-American population. BMC Cancer 2015;15:30.
[PubMed]
https://doi.org/10.1186/s12885-015-1033-3
4.
Chen P, Liang J, Wang Z, et al.: Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res 2008;14:5931-5937.
[PubMed]
https://doi.org/10.1158/1078-0432.CCR-08-0429
5.
Catucci I, Peterlongo P, Ciceri S, et al.: PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. Genet Med 2014;16:688-694.
[PubMed]
https://doi.org/10.1038/gim.2014.13
6.
Cao AY, Yu KD, Yin WJ, et al.: Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population. Breast Cancer Res Treat 2010;123:133-138.
[PubMed]
https://doi.org/10.1007/s10549-009-0637-1
7.
Wu Y, Wang J, Dong X, et al.: Association between a single nucleotide polymorphism in PALB2 rs249954 and breast cancer: a meta-analysis. Chin J Bas Clin Gen Surg 2017;24:1112-1121.
[PubMed]
https://doi.org/10.22034/APJCP.2018.19.10.2897
8.
Rahman N, Seal S, Thompson D, et al.: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007;39:165-167.
[PubMed]
https://doi.org/10.1038/ng1959
9.
Li J, Meeks H, Feng B J, et al.: Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. J Med Genet 2016;53:34-42.
[PubMed]
https://doi.org/10.1136/jmedgenet-2015-103452
10.
Thompson ER, Gorringe KL, Rowley SM, et al.: Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. Breast Cancer Res 2015;17:111.
[PubMed]
https://doi.org/10.1186/s13058-015-0627-7
11.
Damiola F, Schultz I, Barjhoux L, et al.: Mutation analysis of PALB2 gene in French breast cancer families. Breast Cancer Res Treat 2015;154:463-471.
[PubMed]
https://doi.org/10.1007/s10549-015-3625-7
12.
Southey MC, Teo ZL, Dowty JG, et al.: A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res 2010;12:R109.
[PubMed]
https://doi.org/10.1186/bcr2796
13.
Meindl A, Ramser J, Hauke J, et al.: Genetic aspects of hereditary breast and ovarian cancer: options and limits. Med Genet-Berlin 2015;27:202.
14.
Antoniou A C, Casadei S, Heikkinen T, et al. Breast cancer risk in families with mutations in PALB2. N Engl J Med 2014;371:497-506.
[PubMed]
https://doi.org/10.1056/NEJMc1410673
15.
Sluiter M, Mew S, van Rensburg EJ: PALB2 sequence variants in young South African breast cancer patients. Fam Cancer 2009;8:347-353.
[PubMed]
https://doi.org/10.1007/s10689-009-9241-0
16.
Song C, Fu F, Wu X, et al.: Role of three polymorphism in PALB2 gene on early onset breast cancer. China Oncol 2010;20:907-910.
17.
Chen F: Association analysis of single-nucleotide polymorphisms of breast cancer susceptibility genes in FANCD2 pathway with breast cancer risk. Central South University, Doctoral Thesis, 2013.
18.
Dong Y, Wu X, Xie J: Association between PALB2 polymorphism and breast cancer susceptibility. Chin J Clin Lab Sci 2015;33:769-772.
19.
Guenard F, Pedneault C S, Ouellette G, et al.: Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Genet Test Mol Biomarkers 2010;14:515-526.
[PubMed]
https://doi.org/10.1089/gtmb.2010.0027
20.
Jiang W, Zhuang C, Zheng L, et al.: Role of PALB2 polymorphisms with regard to susceptibility to female breast cancer risk in the Chinese population. Genet Test Mol Biomarkers 2016;20:229-234.
[PubMed]
https://doi.org/10.1089/gtmb.2010.0027
© 2018 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.